The purpose of this study was to establish in vitro-in vivo correlation of immediate release Levetiracetam tablets of 1000 mg. In vitro and in vivo studies are done on the test product as Levetiracetam Tablet 1000 mg (containing Levetiracetam 1000 mg) of Orchid HealthCare Ltd., India versus Keppra® Tablet 1000 mg (containing Levetiracetam 1000 mg) of Teva Pharmaceuticals, USA. In vivo studies a...

Subtherapeutic levels of lamotrigine and levetiracetam are more likely to occur during pregnancy owing to the effect of pregnancy on their pharmacokinetics. This can lead to suboptimal control of epilepsy, and guidelines recommend proactive dose adjustment in the second and third trimesters alongside therapeutic drug monitoring (TDM). This retrospective cohort study using administrative databas...

BACKGROUND A proportion of patients with epilepsy are still without seizure control. This open study aims to evaluate the effect and tolerability in consecutive patients treated with the new antiepileptic drug levetiracetam. MATERIALS AND METHODS 184 adult patients were followed up for an average period of 8.1 months. 166 patients (90%) had refractory epilepsy, defined as having seizures more...

RATIONALE: There is a complex interplay between epilepsy, antiepileptic drugs, and reproductive endocrine disorders. Epilepsy itself may influence on the hormonal balance, hormones may affect epilepsy, hormones may influence on the efficacy and metabolism of antiepileptic drugs and antiepileptic drugs may alter the hormone levels.To better understand the interaction of antiepileptic drugs and p...

BACKGROUND Posttraumatic seizure (PTS) is a significant complication of traumatic brain injury (TBI). OBJECTIVE To perform a systematic review and meta-analysis to compare levetiracetam with phenytoin for seizure prophylaxis in patients diagnosed with severe TBI. METHODS An inclusive search of several electronic databases and bibliographies was conducted to identify scientific studies that ...

OBJECTIVE To determine whether patients who fail their first antiepileptic drug (AED) have better neuropsychiatric and quality-of-life (QOL) outcomes if substituted to levetiracetam monotherapy compared with a second older AED. DESIGN Randomized comparative trial. Participants with partial epilepsy who had failed monotherapy with phenytoin sodium, carbamazepine, or valproate sodium were randomi...

BACKGROUND AND OBJECTIVE Patients with focal seizures recruited into adjunctive antiepileptic drug (AED) trials have become more refractory and severe over time; concurrently, placebo responses have increased. To attempt to account for heterogeneity among trials, propensity-score weighted patient-level data were used to indirectly compare placebo responses reported in brivaracetam and levetirac...

OBJECTIVE Aim of the study was to assess the efficacy and safety of levetiracetam as add-on treatment in patients with partial-onset epilepsy in clinical practice. METHODS In this observational, multi-centre study patients were treated with levetiracetam for 16 weeks. From a starting dose of 1000 mg/day, dose levels were adjusted at 2-weekly intervals in 1000-mg steps, to a maximum of 3000 mg...

L-DOPA-induced dyskinesias (LID) remain a major problem of long-term therapy of Parkinson's disease. Levetiracetam, a new antiepileptic drug, has been shown to reduce LID, but the mechanisms underlying its effects are unknown. In this study, we assessed the effect of levetiracetam on key mediators of LID in rats with 6-hydroxydopamine (6-OHDA) lesions. Following chronic administration of L-DOPA...